In recent years, some investigators have reported improved tumor response rates with camrelizumab combination for refractory TACE and confirmed a significant advantage of combination therapy over camrelizumab monotherapy (21, 22), which may be related to increased expression of PD-1 and PD-L1 in HCC after TACE, thus enhancing the antitumor activity of immune checkpoint inhibitors (23). Here, CD274 is linked to neoplasm.